Page last updated: 2024-11-04

temozolomide and Central Diabetes Insipidus

temozolomide has been researched along with Central Diabetes Insipidus in 3 studies

Research Excerpts

ExcerptRelevanceReference
" Temozolomide is an oral DNA-alkylating agent capable of crossing the blood-brain barrier and used as chemotherapy primarily to treat glioblastoma and other brain cancers."8.02Central diabetes insipidus induced by temozolomide: A report of two cases. ( Capes, A; Duck, L; Duprez, T; Labriola, L; Mahiat, C; Whenham, N, 2021)
"Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system."5.39Central diabetes insipidus: a previously unreported side effect of temozolomide. ( Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013)
" Temozolomide is an oral DNA-alkylating agent capable of crossing the blood-brain barrier and used as chemotherapy primarily to treat glioblastoma and other brain cancers."4.02Central diabetes insipidus induced by temozolomide: A report of two cases. ( Capes, A; Duck, L; Duprez, T; Labriola, L; Mahiat, C; Whenham, N, 2021)
"Temozolomide (TMZ) is an alkylating agent primarily used to treat tumors of the central nervous system."1.39Central diabetes insipidus: a previously unreported side effect of temozolomide. ( Faje, AT; Klibanski, A; Makimura, H; Miller, KK; Nachtigall, L; Wexler, D, 2013)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Kuo, C1
Foon, D1
Waters, K1
Cheung, C1
Margol, AS1
Mahiat, C1
Capes, A1
Duprez, T1
Whenham, N1
Duck, L1
Labriola, L1
Faje, AT1
Nachtigall, L1
Wexler, D1
Miller, KK1
Klibanski, A1
Makimura, H1

Other Studies

3 other studies available for temozolomide and Central Diabetes Insipidus

ArticleYear
Central diabetes insipidus: A rare unreported side effect of temozolomide in pediatrics.
    Pediatric blood & cancer, 2020, Volume: 67, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Diabetes Insipidus, Neurogenic; Humans; M

2020
Central diabetes insipidus induced by temozolomide: A report of two cases.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:4

    Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Deamino Arginine Vasopressin; Diabetes In

2021
Central diabetes insipidus: a previously unreported side effect of temozolomide.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:10

    Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Diabetes Insipi

2013